ACRV · Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics reported a Q1 2026 net loss of $19.0 million, a slight improvement from $19.7 million in Q1 2025, driven by lower general and administrative expenses of $4.7 million versus $6.2 million prior year, primarily from reduced employee-related costs including stock-based compensation. Research and development expenses remained stable at $15.2 million, reflecting consistent investment in clinical programs. The company's cash position of $97.7 million as of March 31, 2026, bolstered by $7.3 million from subsequent equity financing, provides runway into Q3 2027, supporting key milestones like ACR-368 Phase 2b interim analysis and ACR-2316 expansion.

Business updates emphasize ACR-368, a CHK1/CHK2 inhibitor, with compelling 52% confirmed overall response rate in 23 serous endometrial cancer patients in the registrational-intent Phase 2b study, versus 22% in non-serous, aligning with higher biomarker positivity in serous EC. Arms 3 and 4 target biopsy-independent serous all-comers, with accelerated enrollment prompting H2 2026 simultaneous interim readout. Arm 2 confirmed ultra-low dose gemcitabine synergy in BM- patients. CEO Peter Blume-Jensen highlighted 2026 as a catalyst year, with Phase 3 readiness by mid-2026 and potential enrollment completion by Q4. External KOL endorsement at ESGO and AACR data support combinations with ICIs or ADCs.

ACR-2316, a WEE1/PKMYT1 inhibitor, advances to expansion with weekly dosing showing transient neutropenia as primary adverse event and durable activity in AP3-prioritized tumors like SCLC and squamous NSCLC, not previously sensitive to class. AACR data showed immune synergy with ICIs. Pipeline includes CDK11 inhibitor IND in H1 2027. This positions Acrivon for multiple value-inflection points within its cash runway.